The FDA database records a supplement, dated 29 September 2026, to Fresenius Kabi USA's abbreviated new drug application for rifampin (ANDA091181). Supplements to generic applications usually cover manufacturing, labelling or packaging changes.
The listing does not state what the supplement covers. It is not a new indication, a safety communication or a change in how rifampicin should be used. It concerns a US-licensed generic product; supply in India is unaffected.
- This is an administrative supplement to a US generic rifampin licence.
- No change to rifampicin's indications, dosing or safety advice follows.
- Rifampicin remains central to drug-susceptible TB treatment and many interaction checks.
Why it matters
It is logged for completeness; the clinical message on rifampicin is unchanged.
Don't overread it
A licence supplement is not a new indication or a safety finding.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for infectious diseases, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free